Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)

被引:33
|
作者
Lenders, Nele [1 ,2 ,3 ]
McCormack, Ann [1 ,2 ]
机构
[1] Garvan Inst Med Res, Sydney, NSW, Australia
[2] Univ New South Wales, St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
关键词
Pituitary carcinomas; Non-functioning pituitary adenomas; Aggressive pituitary tumours; Metastases; Temozolomide; OF-THE-LITERATURE; RECEPTOR RADIONUCLIDE THERAPY; SILENT CORTICOTROPH ADENOMAS; LONG-TERM SURVIVAL; TEMOZOLOMIDE TREATMENT; RADIATION-THERAPY; CUSHING DISEASE; P53; EXPRESSION; CELL-CARCINOMA; TUMOR CELLS;
D O I
10.1007/s11102-017-0857-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.
引用
收藏
页码:217 / 229
页数:13
相关论文
共 50 条
  • [1] Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)
    Nèle Lenders
    Ann McCormack
    Pituitary, 2018, 21 : 217 - 229
  • [2] Non-functioning pituitary adenomas
    Greenman, Yona
    Stern, Naftali
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (05) : 625 - 638
  • [3] Clinically non-functioning pituitary adenomas
    Chanson, Philippe
    Wolf, Peter
    PRESSE MEDICALE, 2021, 50 (04):
  • [4] The management of non-functioning pituitary adenomas
    Jane, JA
    Laws, ER
    NEUROLOGY INDIA, 2003, 51 (04) : 461 - 465
  • [5] Pathogenesis of non-functioning pituitary adenomas
    Zatelli, Maria Chiara
    PITUITARY, 2018, 21 (02) : 130 - 137
  • [6] Pathogenesis of non-functioning pituitary adenomas
    Maria Chiara Zatelli
    Pituitary, 2018, 21 : 130 - 137
  • [7] Radiotherapy for non-functioning pituitary adenomas
    Boelaert, K
    Gittoes, NJL
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 144 (06) : 569 - 575
  • [8] Non-functioning pituitary carcinoma
    Elsässer Imboden P.N.
    Borruat F.-X.
    De Tribolet N.
    Meagher-Villemure K.
    Pica A.
    Gomez F.
    Pituitary, 2004, 7 (3) : 149 - 156
  • [9] A comparative study of functioning and non-functioning pituitary adenomas
    Qin, Jiayin
    Li, Kai
    Wang, Xijuan
    Bao, Yongzhen
    MEDICINE, 2021, 100 (14) : E25306
  • [10] Non-functioning pituitary adenomas: growth and aggressiveness
    Kristin Astrid Øystese
    Johan Arild Evang
    Jens Bollerslev
    Endocrine, 2016, 53 : 28 - 34